Compare Ascendis Pharma A/S (ASND) vs Monster Beverage Corp (MNST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Monster Beverage Corp — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Monster Beverage Corp trades at $98.39 (market cap $95.25B). The key difference: Monster Beverage Corp is far larger — about 5.4× Ascendis Pharma A/S's market cap. Which is the better fit depends on your goals.
| ASND | MNST | |
|---|---|---|
Market Cap | $17.74B | $95.25B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $97.64 |
52-Week Low | $163.32 | $58.65 |
Enterprise Value | $18.11B | $93.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Monster Beverage (MNST) trades at $97.39, up 0.87% today, showing strong momentum after recent earnings beats. The stock exhibits a bullish technical trend, with moving averages supporting further upside, while oscillators are neutral. Fundamentally, the company reported robust revenue growth to $8.29 billion in 2025, with a net income margin of 23.11%, and announced a 2-for-1 stock split effective August 2026, reflecting confidence in future performance.
The outlook remains positive given consistent earnings outperformance and international expansion, but high valuation multiples like a P/E of 47.05 pose risks if growth slows. Investor sentiment is buoyed by analyst consensus favoring buys, though competitive pressures and macroeconomic factors warrant caution for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
